Holding(s) in Company (5107C)
May 01 2012 - 10:50AM
UK Regulatory
TIDMHIK
RNS Number : 5107C
Hikma Pharmaceuticals Plc
01 May 2012
Notification of major interests in shares
LONDON, 1 May 2012 - Hikma Pharmaceuticals PLC ("Hikma") (LSE:
HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals
group, announces as follows:
1 Identity of the issuer or the underlying Hikma Pharmaceuticals PLC
issuer of existing shares to which the
voting rights are attached
----------------------------------------- --------------------------
2 Reason for the notification
--------------------------------------------------------- ----
An acquisition or disposal of voting rights Yes
--------------------------------------------------------- ----
An acquisition or disposal of financial instruments No
which may result in the acquisition of shares already
issues to which voting rights are attached
--------------------------------------------------------- ----
An event changing the breakdown of voting rights No
--------------------------------------------------------- ----
Other (please specify): Compliance with the Transparency No
Directive
--------------------------------------------------------- ----
3 Full name of the person subject to the Sectoral Asset Management
notification obligation Inc. (SAM)
----- ------------------------------------------------------------------ -------------------------------------------
4 Full name of shareholders SAM acts as investment
advisors/sub investment
advisors to a large number
of institutional clients
globally. The actual shareholders
are those institutional
clients, some of whom
have delegated voting
authority to SAM.
----- ------------------------------------------------------------------ -------------------------------------------
5 Date of the Transaction (and date on 27 April 2012
which the threshold crossed is reached
differently)
----- ------------------------------------------------------------------ -------------------------------------------
6 Date on which the issuer notified 1 May 2012
----- ------------------------------------------------------------------ -------------------------------------------
7 Threshold that is crossed 4%
----- ------------------------------------------------------------------ -------------------------------------------
8 Notified details:
----- ------------------------------------------------------------------ -------------------------------------------
A. Voting rights attached to shares
----------------------------------------------------------------------------------------------------------------------
Class type Situation previous Resulting situation after the triggering
of shares to the triggering transaction
(if possible transaction
using the
ISIN code)
---------------- ------------------------ --------------------------------------------------------------------------
Number Number Number of shares Number of voting % of voting
of shares of voting rights rights
rights
----- --------- ---------- ------------ --------------------- --------------------------- ----------------------
Direct Indirect Direct Indirect Direct Indirect
----- --------- ---------- ------------ ---------- --------- ---------------- --------- -------- ------------
2,967,495 1.52%
with SAM 2,967,495 with
with SAM SAM
Ordinary
Shares (0.10 4,955,481 2.72%
GBP) with 5,333,988 with
GB00B0LCW083 7,922,976 clients 8,301,483 0 with clients 0 clients 0%
---------------- ---------- ------------ ---------- --------- ---------------- --------- -------- ------------
B. Qualifying Financial instruments
----------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/Conversion Number of voting % of voting rights
instrument Date Period/Date rights that may
be acquired if
the instrument
if exercised/converted
------------------ ----------- -------------------- ------------------------ -------------------
- - - - -
------------------ ----------- -------------------- ------------------------ -------------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/Conversion Number of voting % of voting rights
financial Price Date Period/Date rights instrument
instrument refers to
------------ --------- ----------- -------------------- ------------------- ---------------------
Nominal Delta
------------ --------- ----------- -------------------- ------------------- ----------- --------
- - - - - - -
------------ --------- ----------- -------------------- ------------------- ----------- --------
Total A+B+C
----------------------------------------------
Number of Voting rights % of voting rights
------------------------ --------------------
2,967,495 with SAM 1.52% with SAM
5,333,988 with clients 2.72% with clients
------------------------ --------------------
9 Chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held, if applicable
------------------------------------------------------------------------------------------
Sectoral Asset Management Inc (SAM) act as investment advisors to clients who hold
Hikma shares.
Some of those clients have delegated their voting authority to SAM, while other SAM
clients
have retained their voting authority. The beneficial owners of the Hikma shares are SAM
clients.
------------------------------------------------------------------------------------------
Proxy Voting
--------------------------------------------------------------------------
10 Name of the proxy holder Sectoral Asset Management Inc (SAM)
in respect of 1.52% of Hikma shares
--- ------------------------------ -------------------------------------
11 Number of voting rights proxy N/A
holder will cease to hold
--- ------------------------------ -------------------------------------
12 Date on which proxy holder N/A
will cease to hold voting
rights
--- ------------------------------ -------------------------------------
13 Additional Information
--- -------------------------- --------------------------------
14 Contact name: Peter Speirs, Company Secretary
--- -------------------------- --------------------------------
15 Contact telephone number: 020 7399 2772
--- -------------------------- --------------------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non--branded generic
and in--licensed products. Hikma's operations are conducted through
three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader, the United States and Europe. In 2011,
Hikma achieved revenue of $918.0 million and profit attributable to
shareholders of $80.1 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUASSRUWAVRAR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
